menu
    • menu
    [{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||mTOR","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Avoro Capital"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Eoc Pharma"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Whitehawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Whitehawk Therapeutics \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Divestment","leadProduct":"Sirolimus Protein-bound Particle","moa":"mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Whitehawk Therapeutics

    Menu

    Whitehawk Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus Protein-bound Particle

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : $100.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Whitehawk Finalizes Aadi Sale To Kaken In Strategic Transformation

                            Details : Through the divestment, Kaken assumes ownership of FYARRO (sirolimus protein-bound particles for injectable suspension) used to treat adults with malignant perivascular epithelioid cell tumor.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : $100.0 million

                            March 26, 2025

                            Lead Product(s) : Sirolimus Protein-bound Particle

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : $100.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adagrasib,Nab-Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in...

                            Details : Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study of Adagrasib (MRTX849), and jointly with Aadi, will oversee and share the cost of the study.

                            Product Name : MRTX849

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 10, 2022

                            Lead Product(s) : Adagrasib,Nab-Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Whitehawk Therapeutics

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus,Adagrasib,Sotorasib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at...

                            Details : ABI-009 (Nab-sirolimus) is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Sirolimus,Adagrasib,Sotorasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Avoro Capital

                            Deal Size : $72.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

                            Details : The company intends to use net proceeds from the financing to fund research and development of Nab-sirolimus and additional clinical opportunities with FYARRO and for working capital and general corporate purposes.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 22, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Avoro Capital

                            Deal Size : $72.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Foundation Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

                            Details : Partners will collect and analyze clinical and molecular data to determine which patients may be eligible to participate in Aadi’s PRECISION 1 clinical trial for ABI-009. The goals are to increase patient match rate, reduce screen failure rate and incr...

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 05, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Foundation Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at t...

                            Details : Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Pro...

                            Details : Nab-sirolimus is an albumin-bound mTOR inhibitor approved by the U.S. Food and Drug Administration (FDA) as FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus...

                            Details : FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Eoc Pharma

                            Deal Size : $271.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO) in Greater Ch...

                            Details : Under the terms of the agreement, EOC Pharma will obtain exclusive rights to develop and commercialize ABI-009 in Greater China.

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            November 01, 2021

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Eoc Pharma

                            Deal Size : $271.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Whitehawk Therapeutics

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Acuta Capital Partners

                            Deal Size : $155.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

                            Details : Proceeds from the PIPE financing are expected to be used for the commercialization of FYARRO in advanced malignant PEComa, a planned tumor-agnostic registrational trial in solid tumors harboring inactivating alterations in the mTOR pathway genes TSC1 and...

                            Product Name : Fyarro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            August 26, 2021

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Acuta Capital Partners

                            Deal Size : $155.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth